Search

Displaying results 7491 - 7500 of 9886 in total
  1. Drug

    MB07811

    go.drugbank.com/drugs/DB05192
    Investigational

    MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. … MB07811 combines a novel thyroid hormone receptor agonist with the Company's novel HepDirect liver targeting prodrug technology.

  2. Drug

    Ordopidine

    go.drugbank.com/drugs/DB05196
    Investigational

    ACR325 is a dopaminergic stabiliser, which has demonstrated promising results in disease models for motor functions and psychoses.

  3. Drug

    CYC116

    go.drugbank.com/drugs/DB05198
    Investigational

    CYC116 is a novel anticancer compound with a unique target profile involving both cell cycle and angiogenesis inhibition mechanisms. … Cyclacel's small molecule investigational drug, CYC116, is the third orally-available Cyclacel drug to enter development, which demonstrated anticancer activity with a mechanism consistent with inhibition

  4. Drug

    LX1031

    go.drugbank.com/drugs/DB05199
    Investigational

    LX1031 was generated by Lexicon medicinal chemists, and its target was internally identified as a key control point for the regulation of peripheral serotonin levels.

  5. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    It is a small molecule designed to act as a pharmacological chaperone that specifically binds, stabilizes, and facilitates the proper folding and trafficking of α-glucosidase (GAA). … AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones.

  6. Drug

    XL418

    go.drugbank.com/drugs/DB05204
    Investigational

    XL418 is a novel anticancer compound.

  7. Drug

    PS386113

    go.drugbank.com/drugs/DB05211
    Experimental

    PS386113 is a small molecule drug candidate under investigation for the treatment of inflammatory disorders. It is being developed by Schering-Plough and Pharmacopeia.

  8. Drug

    KD7040

    go.drugbank.com/drugs/DB05214
    Investigational

    KD7040 is a topically-delivered inducible nitric oxide synthase (iNOS) inhibitor for the treatment of neuropathic pain. The KD7040 IND was filed in 4Q06, and a Phase Ib clinical trial began 2Q07.

  9. Drug

    Pracinostat

    go.drugbank.com/drugs/DB05223
    Investigational

    Data demonstrate that Pracinostat is a potent and effective anti-tumor drug with potential as an oral therapy for a variety of human hematological and solid tumors. … Pracinostat is a novel HDAC inhibitor with improved in vivo properties compared to other HDAC inhibitors currently in clinical trials, allowing oral dosing.

  10. Drug

    RDEA806

    go.drugbank.com/drugs/DB05228
    Investigational

    RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.